{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:39:28Z","timestamp":1791913168147,"version":"4.3.4"},"reference-count":173,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T00:00:00Z","timestamp":1703289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science Centre Poland","award":["2020\/37\/B\/NZ7\/03753"],"award-info":[{"award-number":["2020\/37\/B\/NZ7\/03753"]}]},{"name":"National Science Centre Poland","award":["2016\/21\/B\/NZ7\/01131"],"award-info":[{"award-number":["2016\/21\/B\/NZ7\/01131"]}]},{"name":"Maj Institute of Pharmacology, Polish Academy of Sciences","award":["2020\/37\/B\/NZ7\/03753"],"award-info":[{"award-number":["2020\/37\/B\/NZ7\/03753"]}]},{"name":"Maj Institute of Pharmacology, Polish Academy of Sciences","award":["2016\/21\/B\/NZ7\/01131"],"award-info":[{"award-number":["2016\/21\/B\/NZ7\/01131"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Psychedelics belong to the oldest psychoactive drugs. They arouse recent interest due to their therapeutic applications in the treatment of major depressive disorder, substance use disorder, end-of-life anxiety,= and anxiety symptoms, and obsessive\u2013compulsive disorder. In this review, the current state of preclinical research on the mechanism of action, neurotoxicity, and behavioral impact of psychedelics is summarized. The effect of selective 5-HT2A receptor agonists, 25I- and 25B-NBOMe, after acute and repeated administration is characterized and compared with the effects of a less selective drug, psilocybin. The data show a significant effect of NBOMes on glutamatergic, dopaminergic, serotonergic, and cholinergic neurotransmission in the frontal cortex, striatum, and nucleus accumbens. The increases in extracellular levels of neurotransmitters were not dose-dependent, which most likely resulted from the stimulation of the 5-HT2A receptor and subsequent activation of the 5-HT2C receptors. This effect was also observed in the wet dog shake test and locomotor activity. Chronic administration of NBOMes elicited rapid development of tolerance, genotoxicity, and activation of microglia. Acute treatment with psilocybin affected monoaminergic and aminoacidic neurotransmitters in the frontal cortex, nucleus accumbens, and hippocampus but not in the amygdala. Psilocybin exhibited anxiolytic properties resulting from intensification of GABAergic neurotransmission. The data indicate that NBOMes as selective 5-HT2A agonists exert a significant effect on neurotransmission and behavior of rats while also inducing oxidative DNA damage. In contrast to NBOMes, the effects induced by psilocybin suggest a broader therapeutic index of this drug.<\/jats:p>","DOI":"10.3390\/ijms25010241","type":"journal-article","created":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T20:44:15Z","timestamp":1703450655000},"page":"241","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Molecular and Medical Aspects of Psychedelics"],"prefix":"10.3390","volume":"25","author":[{"given":"Adam","family":"Wojtas","sequence":"first","affiliation":[{"name":"Unit II, Department of Pharmacology, Maj Institute of Pharmacology Polish Academy of Sciences, 12 Sm\u0119tna Street, 31-343 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5018-1394","authenticated-orcid":false,"given":"Krystyna","family":"Go\u0142embiowska","sequence":"additional","affiliation":[{"name":"Unit II, Department of Pharmacology, Maj Institute of Pharmacology Polish Academy of Sciences, 12 Sm\u0119tna Street, 31-343 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,23]]},"reference":[{"key":"ref_1","unstructured":"Schultes, R.E., Hofmann, A., and R\u00e4tsch, C. (1998). Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers. Heal. Art. Press., 1\u2013208."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/a-1310-3990","article-title":"The History of Psychedelics in Psychiatry","volume":"54","author":"Nichols","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/02791072.1979.10472092","article-title":"How LSD originated","volume":"11","author":"Hofmann","year":"1979","journal-title":"J. Psychedelic Drugs"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/npp.2017.86","article-title":"Modern Clinical Research on LSD","volume":"42","author":"Liechti","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/s41591-023-02378-5","article-title":"Psychedelic treatments for mental health conditions pose challenges for informed consent","volume":"29","author":"Seybert","year":"2023","journal-title":"Nat. Med. Comment."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/s41593-022-01177-4","article-title":"The neural basis of psychedelic action","volume":"25","author":"Kwan","year":"2022","journal-title":"Nat. Neurosci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/BF00443425","article-title":"Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex","volume":"97","author":"Pierce","year":"1989","journal-title":"Psychopharmacology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF00176847","article-title":"Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens","volume":"94","author":"Titeler","year":"1988","journal-title":"Psychopharmacology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","article-title":"Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens","volume":"61","author":"Halberstadt","year":"2011","journal-title":"Neuropharmacology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/wmts.42","article-title":"Structure-activity relationships of serotonin 5-HT2A agonists","volume":"1","author":"Nichols","year":"2012","journal-title":"Wiley Interdiscip. Rev. Membr. Transp. Signal."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3109\/15563650.2011.615318","article-title":"Clinical toxicology of newer recreational drugs","volume":"49","author":"Hill","year":"2011","journal-title":"Clin. Toxicol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/0024-3205(84)90436-3","article-title":"Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents","volume":"35","author":"Glennon","year":"1984","journal-title":"Life Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00204-015-1513-x","article-title":"The hallucinogenic world of tryptamines: An updated review","volume":"89","author":"Carvalho","year":"2015","journal-title":"Arch. Toxicol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/7854_2016_466","article-title":"Effect of Hallucinogens on Unconditioned Behavior","volume":"36","author":"Halberstadt","year":"2018","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ray, T.S. (2010). Psychedelics and the human receptorome. PLoS ONE, 5.","DOI":"10.1371\/annotation\/e580a864-cf13-40c2-9bd9-b9687a6f0fe4"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0024-3205(98)00262-8","article-title":"Lysergic acid diethylamide (LSD) is a partial agonist of D2 dopaminergic receptors and it potentiates dopamine-mediated prolactin secretion in lactotrophs in vitro","volume":"63","author":"Giacomelli","year":"1998","journal-title":"Life Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/BF02245940","article-title":"LSD and structural analogs: Pharmacological evaluation at D1 dopamine receptors","volume":"118","author":"Watts","year":"1995","journal-title":"Psychopharmacology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.neuropharm.2015.08.034","article-title":"Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)","volume":"99","author":"Rickli","year":"2015","journal-title":"Neuropharmacology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","article-title":"Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens","volume":"26","author":"Rickli","year":"2016","journal-title":"Eur. Neuropsychopharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0028-3908(97)00051-8","article-title":"Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells","volume":"36","author":"Aghajanian","year":"1997","journal-title":"Neuropharmacology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/00008877-199512000-00010","article-title":"DOI disruption of prepulse inhibition of startle in the rat is mediated by 5-HT(2A) and not by 5-HT(2C) receptors","volume":"6","author":"Sipes","year":"1995","journal-title":"Behav. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/BF02244617","article-title":"5HT-2 mediation of acute behavioral effects of hallucinogens in rats","volume":"100","author":"Wing","year":"1990","journal-title":"Psychopharmacology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41386-019-0360-5","article-title":"Correction: Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels","volume":"44","author":"Madsen","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/a-1721-2914","article-title":"Classic Psychedelic Drugs: Update on Biological Mechanisms","volume":"55","author":"Vollenweider","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"116980","DOI":"10.1016\/j.neuroimage.2020.116980","article-title":"Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention","volume":"218","author":"Barrett","year":"2020","journal-title":"Neuroimage"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.biopsych.2014.04.010","article-title":"Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers","volume":"78","author":"Kraehenmann","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"ref_29","first-page":"20","article-title":"The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs","volume":"8","author":"Leech","year":"2014","journal-title":"Front. Hum. Neurosci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0165-0173(99)00046-6","article-title":"Serotonin model of schizophrenia: Emerging role of glutamate mechanisms","volume":"31","author":"Aghajanian","year":"2000","journal-title":"Brain Res. Brain Res. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"9870","DOI":"10.1073\/pnas.0700436104","article-title":"Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex","volume":"104","author":"Imad","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ebiom.2016.08.049","article-title":"Psychedelics Recruit Multiple Cellular Types and Produce Complex Transcriptional Responses Within the Brain","volume":"11","author":"Martin","year":"2016","journal-title":"EBioMedicine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00213-013-3006-z","article-title":"Characterization of the head-twitch response induced by hallucinogens in mice: Detection of the behavior based on the dynamics of head movement","volume":"227","author":"Halberstadt","year":"2013","journal-title":"Psychopharmacology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1124\/mol.106.028720","article-title":"Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists","volume":"70","author":"Braden","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bcp.2018.09.024","article-title":"Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors","volume":"158","author":"Eshleman","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2013.08.025","article-title":"Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response","volume":"77","author":"Halberstadt","year":"2014","journal-title":"Neuropharmacology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s12640-020-00297-8","article-title":"Neurochemical and Behavioral Effects of a New Hallucinogenic Compound 25B-NBOMe in Rats","volume":"39","author":"Wojtas","year":"2021","journal-title":"Neurotox. Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Custodio, R.J.P., Sayson, L.V., Botanas, C.J., Abiero, A., You, K.Y., Kim, M., Lee, H.J., Yoo, S.Y., Lee, K.W., and Lee, Y.S. (2020). 25B-NBOMe, a novel N-2-methoxybenzyl-phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: Evidence of abuse potential. Addict. Biol., 25.","DOI":"10.1111\/adb.12850"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/FBP.0000000000000309","article-title":"Locomotor and discriminative stimulus effects of four novel hallucinogens in rodents","volume":"28","author":"Gatch","year":"2017","journal-title":"Behav. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/7854_2016_64","article-title":"Pharmacology and Toxicology of N-Benzylphenethylamine (\u201cNBOMe\u201d) Hallucinogens","volume":"32","author":"Halberstadt","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"875722","DOI":"10.3389\/fpsyt.2022.875722","article-title":"Effect of -NBOMe Compounds on Sensorimotor, Motor, and Prepulse Inhibition Responses in Mice in Comparison with the 2C Analogs and Lysergic Acid Diethylamide: From Preclinical Evidence to Forensic Implication in Driving Under the Influence of Drugs","volume":"13","author":"Tirri","year":"2022","journal-title":"Front. Psychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/npp.2009.29","article-title":"5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice","volume":"34","author":"Halberstadt","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neuint.2019.02.007","article-title":"Abuse potential of 2-(4-iodo-2, 5-dimethoxyphenyl)N-(2-methoxybenzyl)ethanamine (25INBOMe); in vivo and ex vivo approaches","volume":"125","author":"Jeon","year":"2019","journal-title":"Neurochem. Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.brainresbull.2019.07.002","article-title":"A novel designer drug, 25N-NBOMe, exhibits abuse potential via the dopaminergic system in rodents","volume":"152","author":"Seo","year":"2019","journal-title":"Brain Res. Bull."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1021\/acschemneuro.3c00196","article-title":"Designer Drug, 25D-NBOMe, Has Reinforcing and Rewarding Effects through Change of a Dopaminergic Neurochemical System","volume":"14","author":"Lee","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1007\/s00213-021-05860-5","article-title":"Tolerance to neurochemical and behavioral effects of the hallucinogen 25I-NBOMe","volume":"238","author":"Herian","year":"2021","journal-title":"Psychopharmacology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuroscience.2014.01.025","article-title":"The role of D2-autoreceptors in regulating dopamine neuron activity and transmission","volume":"282","author":"Ford","year":"2014","journal-title":"Neuroscience"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/jat\/bkv073","article-title":"Analysis of 25I-NBOMe, 25B-NBOMe, 25C-NBOMe and Other Dimethoxyphenyl-N-[(2-Methoxyphenyl) Methyl]Ethanamine Derivatives on Blotter Paper","volume":"39","author":"Poklis","year":"2015","journal-title":"J. Anal. Toxicol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.forsciint.2012.08.027","article-title":"25C-NBOMe\u2014New potent hallucinogenic substance identified on the drug market","volume":"227","author":"Zuba","year":"2013","journal-title":"Forensic Sci. Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5539\/gjhs.v9n11p126","article-title":"NBOMe Compounds: Systematic Review and Data Crunching of the Surface Web","volume":"9","author":"AbdulMajeed","year":"2017","journal-title":"Glob. J. Health Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/15563650.2015.1115056","article-title":"Case series: Toxicity from 25B-NBOMe\u2014A cluster of N-bomb cases","volume":"54","author":"Gee","year":"2016","journal-title":"Clin. Toxicol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/01480545.2014.911882","article-title":"2C-I-NBOMe, an \u201cN-bomb\u201d that kills with \u201cSmiles\u201d. Toxicological and legislative aspects","volume":"38","author":"Nikolaou","year":"2015","journal-title":"Drug Chem. Toxicol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.brainres.2004.07.044","article-title":"Lysergic acid diethylamide and [-]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex","volume":"1023","author":"Muschamp","year":"2004","journal-title":"Brain Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s12640-016-9654-0","article-title":"Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats","volume":"30","author":"Kreiner","year":"2016","journal-title":"Neurotox. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12640-019-00033-x","article-title":"Hallucinogen-Like Action of the Novel Designer Drug 25I-NBOMe and Its Effect on Cortical Neurotransmitters in Rats","volume":"36","author":"Herian","year":"2019","journal-title":"Neurotox. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1021\/acschemneuro.9b00528","article-title":"DARK Classics in Chemical Neuroscience: NBOMes","volume":"11","author":"Poulie","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fnins.2020.00078","article-title":"NBOMes-Highly Potent and Toxic Alternatives of LSD","volume":"14","author":"Zawilska","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3389\/fphar.2019.01406","article-title":"Neurochemical and Behavioral Profiling in Male and Female Rats of the Psychedelic Agent 25I-NBOMe","volume":"10","author":"Miliano","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0306-4522(02)00580-8","article-title":"Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex","volume":"116","author":"Miner","year":"2003","journal-title":"Neuroscience"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0304-3940(03)00547-0","article-title":"The hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats","volume":"346","author":"Scruggs","year":"2003","journal-title":"Neurosci. Lett."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0893-133X(98)00046-3","article-title":"5-HT2 receptor regulation of extracellular GABA levels in the prefrontal cortex","volume":"20","author":"Bubser","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Wojtas, A., Bysiek, A., Wawrzczak-Bargiela, A., Szych, Z., Majcher-Ma\u015blanka, I., Herian, M., Ma\u0107kowiak, M., and Go\u0142embiowska, K. (2022). Effect of Psilocybin and Ketamine on Brain Neurotransmitters, Glutamate Receptors, DNA and Rat Behavior. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23126713"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1038\/s41598-022-07069-8","article-title":"Neurotoxicological profile of the hallucinogenic compound 25I-NBOMe","volume":"12","author":"Herian","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0006-8993(85)91590-2","article-title":"Evidence for the existence of serotonin type-2 receptors on cholinergic terminals in rat cortex","volume":"333","author":"Quirion","year":"1985","journal-title":"Brain Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/syn.20054","article-title":"Activation of 5-HT2 receptors enhances the release of acetylcholine in the prefrontal cortex and hippocampus of the rat","volume":"53","author":"Nair","year":"2004","journal-title":"Synapse"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/archneurpsyc.1958.02340020081015","article-title":"Lysergic acid diethylamide (LSD-25) antagonists. II. Development of tolerance in man to LSD-25 by prior administration of MLD-41 (1-methyl-d-lysergic acid diethylamide)","volume":"79","author":"Abramson","year":"1958","journal-title":"AMA Arch. Neurol. Psychiatry"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF00421802","article-title":"Assessment of tolerance to the hallucinogenic effects of DOM","volume":"36","author":"Angrist","year":"1974","journal-title":"Psychopharmacologia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"109713","DOI":"10.1016\/j.neuropharm.2023.109713","article-title":"Hallucinogenic activity, neurotransmitters release, anxiolytic and neurotoxic effects in Rat\u2019s brain following repeated administration of novel psychoactive compound 25B-NBOMe","volume":"240","author":"Wojtas","year":"2023","journal-title":"Neuropharmacology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/j.1471-4159.2006.03907.x","article-title":"Oxidative stress and neurodegeneration: Where are we now?","volume":"97","author":"Halliwell","year":"2006","journal-title":"J. Neurochem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1021\/tx970185w","article-title":"Oxidation of serotonin by superoxide radical: Implications to neurodegenerative brain disorders","volume":"11","author":"Wrona","year":"1998","journal-title":"Chem. Res. Toxicol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s12640-019-0012-x","article-title":"25C-NBOMe, a Novel Designer Psychedelic, Induces Neurotoxicity 50 Times More Potent Than Methamphetamine In Vitro","volume":"35","author":"Xu","year":"2019","journal-title":"Neurotox. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11419-017-0366-9","article-title":"The psychoactive drug 25B-NBOMe recapitulates rhabdomyolysis in zebrafish larvae","volume":"35","author":"Kawahara","year":"2017","journal-title":"Forensic Toxicol."},{"key":"ref_73","first-page":"158","article-title":"The taxonomy of Psilocybe fagicola-complex","volume":"43","author":"Jacobs","year":"2005","journal-title":"J. Microbiol."},{"key":"ref_74","unstructured":"Wasson, R.G. (2023, November 16). Secret of \u201cDivine Mushrooms\u201d. Life . Available online: https:\/\/www.cuttersguide.com\/pdf\/Periodical-Publications\/life-by-time-inc-published-may-13-1957.pdf."},{"key":"ref_75","first-page":"42","article-title":"Hallucinogenic drugs in pre-Columbian Mesoamerican cultures","volume":"30","year":"2015","journal-title":"Neurologia"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF02160424","article-title":"Elucidation of the structure and the synthesis of psilocybin","volume":"14","author":"Hofmann","year":"1958","journal-title":"Experientia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3181\/00379727-106-26228","article-title":"Dephosphorylation of psilocybin to psilocin by alkaline phosphatase","volume":"106","author":"Horita","year":"1961","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0006-2952(61)90124-1","article-title":"The enzymic dephosphorylation and oxidation of psilocybin and psilocin by mammalian tissue homogenates","volume":"7","author":"Horita","year":"1961","journal-title":"Biochem. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0031-6865(97)00014-9","article-title":"Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man","volume":"72","author":"Hasler","year":"1997","journal-title":"Pharm. Acta Helv."},{"key":"ref_81","first-page":"295","article-title":"Handling of psilocybin and psilocin by everted sacs of rat jejunum and colon","volume":"1","author":"Eivindvik","year":"1989","journal-title":"Acta Pharm. Nord."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin","volume":"7","author":"Passie","year":"2002","journal-title":"Addict. Biol."},{"key":"ref_83","first-page":"270","article-title":"Some biochemical studies on psilocybin and psilogin","volume":"4","author":"Horita","year":"1963","journal-title":"J. Neuropsychiatry"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.euroneuro.2013.12.006","article-title":"Psilocybin\u2014Summary of knowledge and new perspectives","volume":"24","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0006-2952(62)90050-3","article-title":"The fate of psilocin in the rat","volume":"11","author":"Kalberer","year":"1962","journal-title":"Biochem. Pharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0378-4347(98)00067-X","article-title":"Quantitation of psilocin in human plasma by high-performance liquid chromatography and electrochemical detection: Comparison of liquid-liquid extraction with automated on-line solid-phase extraction","volume":"709","author":"Lindenblatt","year":"1998","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/03602532.2016.1278228","article-title":"Metabolism of psilocybin and psilocin: Clinical and forensic toxicological relevance","volume":"49","year":"2017","journal-title":"Drug Metab. Rev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1073\/pnas.1524187113","article-title":"Effects of serotonin 2A\/1A receptor stimulation on social exclusion processing","volume":"113","author":"Preller","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cub.2016.12.030","article-title":"The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation","volume":"27","author":"Preller","year":"2017","journal-title":"Curr. Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0893-133X(98)00108-0","article-title":"5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man\u2014A PET study with [11C]raclopride","volume":"20","author":"Vollenweider","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00213-005-2183-9","article-title":"Distinct temporal phases in the behavioral pharmacology of LSD: Dopamine D2 receptor-mediated effects in the rat and implications for psychosis","volume":"180","author":"Thisted","year":"2005","journal-title":"Psychopharmacology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fphar.2018.00100","article-title":"Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder","volume":"9","author":"Bogenschutz","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.tips.2008.06.006","article-title":"Serotonin research: Contributions to understanding psychoses","volume":"29","author":"Geyer","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF00401509","article-title":"A possible correlation between drug-induced hallucinations in man and a behavioural response in mice","volume":"11","author":"Corne","year":"1967","journal-title":"Psychopharmacologia"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1177\/0269881110388326","article-title":"Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice","volume":"25","author":"Halberstadt","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.pbb.2007.06.003","article-title":"Psilocybin-induced stimulus control in the rat","volume":"87","author":"Winter","year":"2007","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_99","first-page":"17","article-title":"The behavioral pharmacology of hallucinogens","volume":"75","author":"Fantegrossi","year":"2008","journal-title":"Behav. Biol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1248\/bpb.b14-00315","article-title":"Effect of psilocin on extracellular dopamine and serotonin levels in the mesoaccumbens and mesocortical pathway in awake rats","volume":"38","author":"Sakashita","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/cns.14054","article-title":"Psilocin suppresses methamphetamine-induced hyperlocomotion and acquisition of conditioned place preference via D2R-mediated ERK signaling","volume":"29","author":"Wang","year":"2023","journal-title":"CNS Neurosci. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1037\/pha0000253","article-title":"Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats","volume":"27","author":"Sakloth","year":"2019","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s00213-022-06092-x","article-title":"Effects of the 5-HT2A receptor antagonist volinanserin on head-twitch response and intracranial self-stimulation depression induced by different structural classes of psychedelics in rodents","volume":"239","author":"Jaster","year":"2022","journal-title":"Psychopharmacology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1021729","DOI":"10.3389\/fphar.2023.1021729","article-title":"Rearing behaviour in the mouse behavioural pattern monitor distinguishes the effects of psychedelics from those of lisuride and TBG","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1021\/acschemneuro.9b00493","article-title":"Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression","volume":"11","author":"Hibicke","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00221-013-3579-0","article-title":"Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning","volume":"228","author":"Catlow","year":"2013","journal-title":"Exp. Brain Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ijnp\/pyab040","article-title":"A Complex Impact of Systemically Administered 5-HT2A Receptor Ligands on Conditioned Fear","volume":"24","author":"Pettersson","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1017\/neu.2019.15","article-title":"Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat","volume":"31","author":"Jefsen","year":"2019","journal-title":"Acta Neuropsychiatry"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","article-title":"Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo","volume":"109","author":"Shao","year":"2021","journal-title":"Neuron"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e2022489118","DOI":"10.1073\/pnas.2022489118","article-title":"Harnessing psilocybin: Antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice","volume":"118","author":"Hesselgrave","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1360-0443.2004.00744.x","article-title":"Comparison of acute lethal toxicity of commonly abused psychoactive substances","volume":"99","author":"Gable","year":"2004","journal-title":"Addiction"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/0269881113477744","article-title":"Harms and benefits associated with psychoactive drugs: Findings of an international survey of active drug users","volume":"27","author":"Morgan","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0140-6736(07)60464-4","article-title":"Development of a rational scale to assess the harm of drugs of potential misuse","volume":"369","author":"Nutt","year":"2007","journal-title":"Lancet"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","article-title":"Acute psychological and physiological effects of psilocybin in healthy humans: A double-blind, placebo-controlled dose-effect study","volume":"172","author":"Hasler","year":"2004","journal-title":"Psychopharmacology"},{"key":"ref_115","first-page":"42","article-title":"Clinical, biochemical and psychologic effects of psilocybin","volume":"130","author":"Hollister","year":"1961","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-2007-979351","article-title":"The standardized psychometric assessment of altered states of consciousness (ASCs) in humans","volume":"31","author":"Dittrich","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1177\/0269881110382466","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies","volume":"25","author":"Studerus","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0361-9230(01)00646-3","article-title":"A systems model of altered consciousness: Integrating natural and drug-induced psychoses","volume":"56","author":"Vollenweider","year":"2001","journal-title":"Brain Res. Bull."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.tins.2020.11.008","article-title":"A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics","volume":"44","author":"Savalia","year":"2021","journal-title":"Trends Neurosci."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Borsellino, P., Krider, R.I., Chea, D., Grinnell, R., and Vida, T.A. (2023). Ketamine and the Disinhibition Hypothesis: Neurotrophic Factor-Mediated Treatment of Depression. Pharmaceuticals, 16.","DOI":"10.3390\/ph16050742"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/bs.pbr.2018.07.008","article-title":"d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders","volume":"242","author":"Enns","year":"2018","journal-title":"Prog. Brain Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nm.4050","article-title":"Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants","volume":"22","author":"Duman","year":"2016","journal-title":"Nat. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics Promote Structural and Functional Neural Plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"key":"ref_124","first-page":"3125","article-title":"Expression of Serotonin2C Receptors in Pyramidal and GABAergic Neurons of Rat Prefrontal Cortex: A Comparison with Striatum","volume":"27","author":"Santana","year":"2017","journal-title":"Cereb. Cortex"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/cercor\/bhg128","article-title":"Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex","volume":"14","author":"Bortolozzi","year":"2004","journal-title":"Cereb. Cortex"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/cercor\/bhh070","article-title":"Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex","volume":"14","author":"Santana","year":"2004","journal-title":"Cereb. Cortex"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/syn.890090307","article-title":"Excitatory responses to serotonin (5-HT) in neurons of the rat piriform cortex: Evidence for mediation by 5-HT1C receptors in pyramidal cells and 5-HT2 receptors in interneurons","volume":"9","author":"Sheldon","year":"1991","journal-title":"Synapse"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1523\/JNEUROSCI.5113-03.2004","article-title":"Serotonergic regulation of membrane potential in developing rat prefrontal cortex: Coordinated expression of 5-hydroxytryptamine (5-HT)1A, 5-HT2A, and 5-HT7 receptors","volume":"24","author":"Campbell","year":"2004","journal-title":"J. Neurosci."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/0269881117725915","article-title":"Serotonin and brain function: A tale of two receptors","volume":"31","author":"Nutt","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Erritzoe","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1002\/hbm.22833","article-title":"Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin","volume":"36","author":"Lebedev","year":"2015","journal-title":"Hum. Brain Mapp."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/jpet.103.051797","article-title":"The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways","volume":"306","author":"Millan","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/syn.21551","article-title":"Involvement of 5-HT2A receptor and \u03b12-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow","volume":"66","author":"Marcus","year":"2012","journal-title":"Synapse"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/s41386-020-0718-8","article-title":"Me, myself, bye: Regional alterations in glutamate and the experience of ego dissolution with psilocybin","volume":"45","author":"Mason","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1152\/jn.1999.82.6.2989","article-title":"Activation of serotonin receptors modulates synaptic transmission in rat cerebral cortex","volume":"82","author":"Zhou","year":"1999","journal-title":"J. Neurophysiol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jad.2020.07.083","article-title":"Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence","volume":"276","author":"Rodrigues","year":"2020","journal-title":"J. Affect. Disord."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s11920-012-0322-7","article-title":"Where in the brain is depression?","volume":"14","author":"Pandya","year":"2012","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1097\/00001756-199806220-00021","article-title":"Amygdala core nuclei volumes are decreased in recurrent major depression","volume":"9","author":"Sheline","year":"1998","journal-title":"Neuroreport"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/npp.2017.49","article-title":"The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder","volume":"42","author":"Abdallah","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jad.2020.06.068","article-title":"Relationship between hippocampal volume and inflammatory markers following six infusions of ketamine in major depressive disorder","volume":"276","author":"Zhou","year":"2020","journal-title":"J. Affect. Disord."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Wojtas, A., Bysiek, A., Wawrzczak-Bargiela, A., Ma\u0107kowiak, M., and Go\u0142embiowska, K. (2024). Limbic system response to psilocybin and ketamine administration in rats: A neurochemical and behavioral study. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202309.1649.v1"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/0361-9230(89)90198-6","article-title":"Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release","volume":"23","author":"Guan","year":"1989","journal-title":"Brain Res. Bull."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/j.1471-4159.1993.tb09794.x","article-title":"Serotonin and dopamine sensitization in the nucleus accumbens, ventral tegmental area, and dorsal raphe nucleus following repeated cocaine administration","volume":"61","author":"Parsons","year":"1993","journal-title":"J. Neurochem."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.pneurobio.2016.03.004","article-title":"Serotonergic modulation of the activity of mesencephalic dopaminergic systems: Therapeutic implications","volume":"151","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnint.2013.00025","article-title":"Serotonin modulation of cortical neurons and networks","volume":"7","author":"Celada","year":"2013","journal-title":"Front. Integr. Neurosci."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/(SICI)1096-9861(19990628)409:2<187::AID-CNE2>3.0.CO;2-P","article-title":"Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat","volume":"409","author":"Riad","year":"1999","journal-title":"J. Comp. Neurol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1046\/j.1471-4159.1994.62051804.x","article-title":"Hippocampal serotonin 5-HT1A receptor enhances acetylcholine release in conscious rats","volume":"62","author":"Izumi","year":"1994","journal-title":"J. Neurochem."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1152\/jn.00686.2010","article-title":"M1 and M4 receptors modulate hippocampal pyramidal neurons","volume":"105","author":"Dasari","year":"2011","journal-title":"J. Neurophysiol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00221-013-3512-6","article-title":"Functional anatomy of 5-HT2A receptors in the amygdala and hippocampal complex: Relevance to memory functions","volume":"230","author":"Bombardi","year":"2013","journal-title":"Exp. Brain Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0169-328X(94)90223-2","article-title":"Distribution of the serotonin 5-HT2 receptor family mRNAs: Comparison between 5-HT2A and 5-HT2C receptors","volume":"23","author":"Pompeiano","year":"1994","journal-title":"Brain Res. Mol. Brain Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00441-005-1112-x","article-title":"5-HT1A receptor expression in pyramidal neurons of cortical and limbic brain regions","volume":"321","author":"Palchaudhuri","year":"2005","journal-title":"Cell Tissue Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study","volume":"3","author":"Bolstridge","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up","volume":"235","author":"Bolstridge","year":"2018","journal-title":"Psychopharmacology"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder. A randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/02698811211073759","article-title":"Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up","volume":"36","author":"Gukasyan","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of Psilocybin versus Escitalopram for Depression","volume":"384","author":"Giribaldi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1192\/bjo.2022.565","article-title":"Effects of psilocybin versus escitalopram on rumination and thought suppression in depression","volume":"8","author":"Barba","year":"2022","journal-title":"BJPsych Open"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"ref_161","first-page":"157","article-title":"Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction","volume":"7","author":"Griffiths","year":"2014","journal-title":"Curr. Drug Abus. Rev."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fnins.2020.00043","article-title":"Rethinking therapeutic strategies for anorexia nervosa, insights from psychedelic medicine and animal models","volume":"14","author":"Foldi","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. A randomized double-blind trial","volume":"30","author":"Griffits","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J. Nerv. Ment. Dis."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ijnp\/pyaa018","article-title":"Reviewing the potential of psychedelics for treatment of PTSD","volume":"23","author":"Krediet","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.tins.2008.12.005","article-title":"Psychedelics and schizophrenia","volume":"32","author":"Sealfon","year":"2009","journal-title":"Trends Neurosci."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1017\/S1461145713000643","article-title":"Disruption of thalamocortical activity in schizophrenia models: Relevance to antipsychotic drug action","volume":"16","author":"Celada","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Mahmood, D., Alenzi, S.K., Anwar, M.J., Azam, F., Qureshi, K.A., and Jaremko, M. (2022). New paradigms of old psychedelics in schizophrenia. Pharmaceuticals, 15.","DOI":"10.3390\/ph15050640"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","article-title":"The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects","volume":"4","author":"Olson","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1126\/science.adf0435","article-title":"Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors","volume":"379","author":"Vargas","year":"2023","journal-title":"Science"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/1\/241\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:40:59Z","timestamp":1760132459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/1\/241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,23]]},"references-count":173,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["ijms25010241"],"URL":"https:\/\/doi.org\/10.3390\/ijms25010241","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,23]]}}}